MRI定量非酒精性脂肪性肝炎临床试验中的安慰剂效应
该研究对7项早期临床试验中187例接受安慰剂的NASH患者进行二次分析,发现安慰剂治疗12、16、24周后分别有20%、9%、28%的患者PDFF相对降低≥30%,模型估计24周PDFF绝对下降2.3单位(中位相对降低13%),提示未来试验样本量计算需考虑约3单位的安慰剂效应。
要点
- 接受安慰剂治疗的NASH患者中,24周时PDFF相对降低≥30%者占28%。
- 模型估计安慰剂治疗24周PDFF绝对下降2.3单位,中位相对降低13%。
- 建议未来临床试验样本量计算时考虑约3单位的PDFF绝对下降。
关键影像表现/征象
- 安慰剂治疗12周后20%(10/49)的患者PDFF相对降低≥30%。
- 安慰剂治疗16周后9%(2/22)的患者PDFF相对降低≥30%。
- 安慰剂治疗24周后28%(34/122)的患者PDFF相对降低≥30%。
诊断标准与关键数值
- 主要结局定义为PDFF相对降低≥30%。
- 重复测量线性混合效应模型估计安慰剂治疗24周PDFF绝对下降2.3单位(95%CI:3.2,1.4;P < .001),中位相对降低13%。
- 建议未来试验样本量计算时考虑约3单位(95%CI上限)的绝对PDFF下降以校正安慰剂效应。
临床应用与阅片要点
- 在NASH临床试验中解读PDFF变化时需警惕安慰剂效应,避免将PDFF下降简单归因于药物疗效。
- PDFF作为临床试验主要终点的样本量估算应纳入约3单位的绝对下降作为安慰剂效应校正。
局限性
- 本研究为对7项早期临床试验的二次分析,非预设主要分析。
- 各时间点亚组样本量不均且较小(如16周仅22例),可能影响估计稳定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Several early-phase clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) use liver fat content as measured with the MRI-derived proton density fat fraction (PDFF) for a primary outcome. These trials have shown relative reductions in liver fat content with placebo treatment alone, a phenomenon termed "the placebo effect." This phenomenon confounds the results and limits generalizability to future trials. Purpose To quantify the effect of placebo treatment on change in the absolute PDFF value and to identify variables associated with this observed change. Materials and Methods This is a secondary analysis of prospectively collected data from seven early phase clinical trials that included participants with a diagnosis of NASH based on MRI and/or liver biopsy who received placebo treatment. The primary outcome was a greater than or equal to 30% relative reduction in PDFF after placebo treatment. Normalization of PDFF, relative change in alanine aminotransferase (ALT) level, and normalization of ALT level were also examined. An exploratory linear mixed-effects model was used to estimate an overall change in absolute PDFF and to explore parameters associated with this response. Results A total of 187 participants (median age, 52 years [IQR, 43-60 years]; 114 women) who received placebo treatment were evaluated. A greater than or equal to 30% relative reduction in baseline PDFF was seen in 20% of participants after 12 weeks of placebo treatment (10 of 49), 9% of participants after 16 weeks (two of 22), and 28% of participants after 24 weeks (34 of 122). A repeated-measures linear mixed-effects model estimated a decrease of 2.3 units (median relative reduction of 13%) in absolute PDFF values after 24 weeks of placebo treatment (95% CI: 3.2, 1.4; P < .001). Conclusion In this analysis of 187 participants, a clinically relevant decrease in PDFF was observed with placebo treatment. Based on the study model, assuming an absolute PDFF decrease of approximately 3 units (upper limit of 95% CI) to account for this "placebo effect" in sample size calculations for future clinical trials is suggested. Clinical trial registration nos. NCT01066364, NCT01766713, NCT01963845, NCT02443116, NCT02546609, NCT02316717, and NCT02442687 © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Yoon in this issue.
引用
- Nedrud, Chaudhry, Middleton, et al. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. Radiology. 2022. PMID: 36318027. doi:10.1148/radiol.220743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。